• Reported GAAP EPS of -$2.45 up 75.62% YoY • Aethlon Medical Inc explicitly states existing cash as of December 31, 2025, is not expected to fund operations for at least twelve months, anticipating increasing negative cash flows and net losses for the foreseeable future.
Bullish
Aethlon Medical Inc's Hemopurifier showed favorable safety in trials and received FDA Breakthrough Device designation, while the company also secured $6,728,000 in financing.
Bearish
Aethlon Medical Inc faces substantial doubt about its going concern ability due to insufficient cash for twelve months, increasing net losses, and the cancellation of its India clinical trial.